Abstract:Qingqiang Dai, Tianqi Zhang, Chen Li Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China Correspondence: Chen Li Department of Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China Tel +86-21-64670644 Fax +86-21-64393909 Email leedoctor@sina.com Background: Many studies showed that long non-coding RNA MALAT1 is served as an oncogene. However, the specific role of MALAT1 in gastric cancer is not fully elucidated. The aim of this study is to elucidate the regulatory effects of MALAT1 on tumor development and cisplatin resistance in gastric cancer. Methods: TCGA database was applied to investigate the expression levels of MALAT1 in GC tissues and normal gastric tissues and its correlation with GC patients' survival. Univariate and multivariate analysis were performed to investigate whether MALAT1 expression is an independent risk for overall survival of gastric cancer patients. The expression of MALAT1 was detected by Quantitative real-time PCR. After knockdown or overexpression of MALAT1, the cellular functions of GC cells were detected by cell-proliferation, flow cytometry, transwell assay and colony formation assays, respectively. Western blot analysis was performed to detect the protein levels of Bcl-2 and key genes in the PI3K/AKT pathway in GC cells. Finally, CCK-8 assay was performed to explore the effect of MALAT1 on cisplatin resistance of GC cells. Results: Higher expression of MALAT1 was detected in GC tissues than that of adjacent normal tissues, high MALAT1 expression is an independent risk for overall survival of gastric cancer patients. Knockdown of MALAT1 inhibited proliferation, migration and invasion of GC cells, while overexpression of MALAT1 Overexpression of MALAT1 yielded opposite results. Western blot results showed that protein expressions of p-PI3K, p-AKT and p-STAT3 were downregulated after MALAT1 knockdown in GC cells, while these proteins were upregulated after MALAT1 overexpression. Additionally, the IC 50 in MGC803/CDDP cells transfected with si-MALAT1 was lower than in those transfected with si-NC. The apoptotic rate in MGC803 cells transfected with pcDNA-MALAT1 was remarkably lower than those transfected with NC. Conclusion: We demonstrated that MALAT1 is highly expressed in GC, high MALAT1 expression is an independent risk factor for OS among GC patients. Moreover, MALAT1 promotes malignant progression of GC and contributes to cisplatin resistance of GC cells, indicating MALAT1 may serve as a biological hallmark for predicting the prognosis of GC. Keywords: gastric cancer, MALAT1, proliferation, migration and invasion, cisplatin resistance

Long noncoding RNA MALAT1 potentiates growth and inhibits senescence by antagonizing ABI3BP in gallbladder cancer cells

The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer.

Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206.

MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway.

Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development

Long noncoding RNA lncGALM increases risk of liver metastasis in gallbladder cancer through facilitating N‐cadherin and IL‐1β‐dependent liver arrest and tumor extravasation

LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway

Retraction: ‘long Non-Coding RNA LINC00152 Promotes Gallbladder Cancer Metastasis and Epithelial-Mesenchymal Transition by Regulating HIF-1α Via Mir-138’

Upregulation of Long Non-Coding RNA LINC00152 by SP1 Contributes to Gallbladder Cancer Cell Growth and Tumor Metastasis Via PI3K/AKT Pathway.

Inhibition of MALAT1 Reduces Tumor Growth and Metastasis and Promotes Drug Sensitivity in Colorectal Cancer

MALAT1 Modulated FOXP3 Ubiquitination then Affected GINS1 Transcription and Drived NSCLC Proliferation

Long noncoding RNA MALAT1 suppresses breast cancer metastasis

Long Non-Coding RNA MALAT1 Activates Autophagy and Promotes Cell Proliferation by Downregulating Microrna-204 Expression in Gastric Cancer

Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial–mesenchymal transition by regulating HIF-1α via miR-138

LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis

LncRNA MALAT1 Functions As a Competing Endogenous RNA to Regulate ZEB2 Expression by Sponging Mir-200S in Clear Cell Kidney Carcinoma

Long Non-coding RNA MALAT1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124

Blocking Lncrna MALAT1/miR-199a/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression

Long Non-Coding RNA CCAT1 Promotes Gallbladder Cancer Development Via Negative Modulation of Mirna-218-5p.

Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer.

MALAT1/ miR-1-3p-mediated BRF2 promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway